BrainChild Bio gets $116M for pivotal trial of pediatric brain tumor CAR-T

A Seattle biotech trying to flip the script on CAR-T cell therapies — making them akin to small molecules for brain tumors — has put together a megaround with the hopes of becoming a commercial-stage company around ...